“…This gap is in great part responsible for the disproportion between the number of PD patients to which surgery should be offered and the actual number of patients in which the surgery is actually and correctly performed. 2 In this issue of the journal, an article in two parts by Aquino and Moscovich et al 3,4 explored the state-of-the-art and new and future technologies in neuromodulation for PD. The authors reviewed the DBS indication criteria, expected outcomes, and possible targets according to patients' profiles, programming, and medication management.…”